The Corneal Edema drugs in development market research report provides comprehensive information on the therapeutics under development for Corneal Edema, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Corneal Edema. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Corneal Edema and features dormant and discontinued products.
GlobalData tracks six drugs in development for Corneal Edema by five companies/universities/institutes. The top development phase for Corneal Edema is phase i with three drugs in that stage. The Corneal Edema pipeline has six drugs in development by companies and 0 by universities/ institutes. Some of the companies in the Corneal Edema pipeline products market are: Cellusion, Aurion Biotechnologies and Kowa.
The key targets in the Corneal Edema pipeline products market include Rho Kinase (Rho Associated Coiled Coil Forming Protein Kinase or ROCK or EC 2.7.11.1), and Sodium Dependent Noradrenaline Transporter (Norepinephrine Transporter or NET or Solute Carrier Family 6 Member 2 or SLC6A2).
The key mechanisms of action in the Corneal Edema pipeline product include Rho Kinase (Rho Associated Coiled Coil Forming Protein Kinase or ROCK or EC 2.7.11.1) Inhibitor with three drugs in Phase III. The Corneal Edema pipeline products include five routes of administration with the top ROA being Ophthalmic and two key molecule types in the Corneal Edema pipeline products market including Cell Therapy, and Small Molecule.
Corneal Edema overview
Corneal edema is the swelling of the cornea due to the accumulation of extracellular fluid in epithelium and stroma resulting in loss of corneal transparency.
For a complete picture of Corneal Edema’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
